3 July 2017 - Pfizer’s Besponsa leukaemia drug has been approved in Europe, but the company is heading for a showdown with England’s NICE, which has said in a draft decision that the medicine it is too expensive for regular NHS funding.

Besponsa (inotuzumab ozogamicin) has been approved in Europe for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia.

NICE is now issuing draft appraisals of cancer drugs much earlier -in some cases even before they gain European approval – and last month published first draft guidance rejecting the drug on cost grounds.

Read Pharmaphorum article